Immune Cell Engager Assays

Immune cell engager assays are becoming more and more important due to the ongoing success of BiTE technology

The most promising bispecific antibodies are immune cell engagers. Bispecific antibodies contain two antigen-binding components within a single molecule enabling the simultaneous binding of two targets and can be designed to neutralise cytokine activity, block signalling pathways or to recruit the effector cells of the immune system.

Our approach

Our assays are based on the co-culture of PBMCs, T-cells or NK cells with cells expressing tumour antigen targeted by the bispecific, and can analyse the biological effects on both target and effector cells.

T-Cell Dependent Cellular Cytotoxicity

The biological activity of T-cell engaging bispecific antibodies can be determined using TDCC (T-Cell Dependent Cellular Cytotoxicity) assays supported with CD3-antigen binding assays. The TDCC assay follows a similar format to that of the ADCC assay, in which the bispecific forms a bridge between target cells expressing and T-cells present within the effector preparation. As with ADCC assays, TDCC assays are complex methods with many formats requiring the use of primary cell types and expertise to run successfully.